GAD has an estimated lifetime prevalence of 9% and a 1-year prevalence of 2.9% in the US.[1]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022. In Europe, estimates for 1-month prevalence are approximately 0.2% to 1.5%, with a lifetime prevalence of around 1% to 7%. Around 4.0% to 7.9% of primary care patients and 22.0% of people presenting with anxiety are diagnosed with GAD.[4]Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry. 2017 May 1;74(5):465-75.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2608757
http://www.ncbi.nlm.nih.gov/pubmed/28297020?tool=bestpractice.com
[5]Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005 Aug;15(4):445-52.
http://www.ncbi.nlm.nih.gov/pubmed/15951160?tool=bestpractice.com
GAD is more common in high-income countries than in lower-income countries, where the reported prevalence can be under 1%.[4]Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry. 2017 May 1;74(5):465-75.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2608757
http://www.ncbi.nlm.nih.gov/pubmed/28297020?tool=bestpractice.com
Differences in estimates of disease prevalence in the US and internationally are likely to be due to several factors, including methodological differences and cultural differences in attitudes towards mental health disorders, in addition to actual differences between populations.[6]Stein DJ, Scott KM, de Jonge P, et al. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017 Jun;19(2):127-36.
https://www.tandfonline.com/doi/full/10.31887/DCNS.2017.19.2/dstein
http://www.ncbi.nlm.nih.gov/pubmed/28867937?tool=bestpractice.com
[7]Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35.
https://www.tandfonline.com/doi/full/10.31887/DCNS.2015.17.3/bbandelow
http://www.ncbi.nlm.nih.gov/pubmed/26487813?tool=bestpractice.com
There is a robust and growing body of evidence to suggest that the COVID-19 pandemic was associated with a rapid increase in prevalence of anxiety disorders globally.[8]COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-12.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02143-7/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34634250?tool=bestpractice.com
[9]da Silva ML, Rocha RSB, Buheji M, et al. A systematic review of the prevalence of anxiety symptoms during coronavirus epidemics. J Health Psychol. 2021 Jan;26(1):115-25.
https://journals.sagepub.com/doi/10.1177/1359105320951620
http://www.ncbi.nlm.nih.gov/pubmed/32830577?tool=bestpractice.com
One study has estimated that the pandemic has resulted in an additional 76.2 million cases of anxiety disorders globally (an increase of 25.6%).[8]COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-12.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02143-7/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34634250?tool=bestpractice.com
The longer-term impact of this is currently unclear.
GAD usually starts in adulthood and persists over time. Onset is reported to be later, and clinical course more persistent, in lower-income countries. GAD is the commonest anxiety disorder in old age, with prevalence ranging from 1.3% to 4.7%.[10]Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016 Jun 5;6(7):e00497.
https://onlinelibrary.wiley.com/doi/10.1002/brb3.497
http://www.ncbi.nlm.nih.gov/pubmed/27458547?tool=bestpractice.com
About two-thirds of patients diagnosed with GAD are female, and more women (55% to 60%) than men are diagnosed in clinical settings.[1]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.[7]Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35.
https://www.tandfonline.com/doi/full/10.31887/DCNS.2015.17.3/bbandelow
http://www.ncbi.nlm.nih.gov/pubmed/26487813?tool=bestpractice.com
[11]Grenier S, Payette MC, Gunther B, et al. Association of age and gender with anxiety disorders in older adults: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2019 Mar;34(3):397-407.
http://www.ncbi.nlm.nih.gov/pubmed/30444008?tool=bestpractice.com
There is a higher prevalence of GAD during pregnancy and shortly after birth. Prevalence estimates during pregnancy and the postnatal period range from around 2.2% to 10%.[12]Dennis CL, Falah-Hassani K, Shiri R. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. Br J Psychiatry. 2017 May;210(5):315-23.
https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/prevalence-of-antenatal-and-postnatal-anxiety-systematic-review-and-metaanalysis/9CF2AC0D36E9FF13A32022460FCBA7EE
http://www.ncbi.nlm.nih.gov/pubmed/28302701?tool=bestpractice.com
[13]Fawcett EJ, Fairbrother N, Cox ML, et al. The prevalence of anxiety disorders during pregnancy and the postpartum period: a multivariate Bayesian meta-analysis. J Clin Psychiatry. 2019 Jul 23;80(4):18r12527.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839961
http://www.ncbi.nlm.nih.gov/pubmed/31347796?tool=bestpractice.com
Studies in several countries have shown that GAD commonly occurs along with, and often precedes, other mental health disorders.[4]Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry. 2017 May 1;74(5):465-75.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2608757
http://www.ncbi.nlm.nih.gov/pubmed/28297020?tool=bestpractice.com
[5]Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005 Aug;15(4):445-52.
http://www.ncbi.nlm.nih.gov/pubmed/15951160?tool=bestpractice.com
[6]Stein DJ, Scott KM, de Jonge P, et al. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017 Jun;19(2):127-36.
https://www.tandfonline.com/doi/full/10.31887/DCNS.2017.19.2/dstein
http://www.ncbi.nlm.nih.gov/pubmed/28867937?tool=bestpractice.com
[7]Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35.
https://www.tandfonline.com/doi/full/10.31887/DCNS.2015.17.3/bbandelow
http://www.ncbi.nlm.nih.gov/pubmed/26487813?tool=bestpractice.com
[14]Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8-19.
http://www.ncbi.nlm.nih.gov/pubmed/8279933?tool=bestpractice.com
[15]Alonso J, Angermeyer MC, Bemert S, et al. 12-month comorbidity and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:28-37.
http://www.ncbi.nlm.nih.gov/pubmed/15128385?tool=bestpractice.com
The lifetime prevalence of depression is approximately 43% in people with GAD.[16]Kalin NH. The critical relationship between anxiety and depression. Am J Psychiatry. 2020 May 1;177(5):365-7.
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20030305
Comorbidity among anxiety disorders is substantial; 48% to 68% of adults with one anxiety disorder fulfil the criteria for another concurrent anxiety disorder.[17]Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011 Mar;72(3):341-8.
http://www.ncbi.nlm.nih.gov/pubmed/21294994?tool=bestpractice.com
Prevalence of anxiety disorders also appears to be higher in people with chronic physical health conditions, including cardiovascular disease, cancer, respiratory disease, diabetes, and polycystic ovary syndrome.[10]Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016 Jun 5;6(7):e00497.
https://onlinelibrary.wiley.com/doi/10.1002/brb3.497
http://www.ncbi.nlm.nih.gov/pubmed/27458547?tool=bestpractice.com
GAD is associated with significant disability, affecting people's work and ability to carry out daily activities.
Treatment is sought by approximately half of people affected by GAD.[4]Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry. 2017 May 1;74(5):465-75.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2608757
http://www.ncbi.nlm.nih.gov/pubmed/28297020?tool=bestpractice.com
A large US epidemiological study found that almost half of people with GAD retained the diagnosis after 2 years.[14]Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8-19.
http://www.ncbi.nlm.nih.gov/pubmed/8279933?tool=bestpractice.com